| PRNP — Prion Protein | |
|---|---|
| Symbol | PRNP |
| Full Name | Prion Protein (Kanno Blood Group) |
| Chromosome | 20p13 |
| NCBI Gene | 5621 |
| Ensembl | ENSG00000171867 |
| OMIM | 176640 |
| UniProt | P04156 |
| Diseases | Creutzfeldt-Jakob Disease, Fatal Familial Insomnia, GSS Syndrome |
| Expression | Cerebral cortex, Cerebellum, Hippocampus, Thalamus, Basal ganglia, Brainstem |
| Key Mutations | |
| E200K (most common gCJD) D178N (FFI/gCJD modifier) P102L (GSS) A117V (GSS variant) V210I (low-penetrance gCJD) |
|
Prnp — Prion Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PRNP (Prion Protein, also known as CD230 or Kanno blood group antigen) is a gene located on chromosome 20p13 that encodes the major prion protein (PrP), a glycosylphosphatidylinositol (GPI)-anchored glycoprotein of
253 amino acids [1].
The PRNP gene is approximately 16 kilobases long and contains two exons, with the entire open reading frame encoded within exon 2 [2].
PrP is expressed prominently in the central nervous system — particularly in [neurons[/entities/neurons — but is also found in many other tissues throughout the body [1].
The PRNP gene is the causative gene for all inherited forms of human [prion diseases[/diseases/prion-diseases, which are a unique class of fatal neurodegenerative disorders that can be sporadic, inherited, or acquired through infection [2][3].
Pathogenic mutations in PRNP account for approximately 10–15% of all [Creutzfeldt-Jakob disease[/diseases/creutzfeldt-jakob (CJD) cases, and inherited prion diseases follow an autosomal dominant pattern with variable penetrance [3].
The remaining ~85% of cases are sporadic (sCJD), and ~1% are acquired through transmission of misfolded PrP [2].
The normal cellular form of the prion protein, designated PrP^C, adopts a predominantly alpha-helical structure with a flexible N-terminal tail and a structured C-terminal domain containing three alpha-helices and a
short antiparallel beta-sheet [4].
PrP^C is tethered to the outer leaflet of the cell membrane by a GPI anchor and undergoes constitutive endocytic recycling [1].
Although the precise physiological role of PrP^C remains incompletely understood, it has been implicated in multiple cellular processes including:
In prion diseases, PrP^C undergoes a conformational change to an abnormal isoform designated PrP^Sc (Sc for scrapie), which is characterized by a dramatic increase in beta-sheet content and the formation of amyloid
fibrils [2][3].
PrP^Sc is protease-resistant, insoluble, and acts as a template to convert additional PrP^C molecules into the misfolded form — a process termed "seeded polymerization" or "protein-only" prion propagation [2].
This self-propagating misfolding cascade leads to progressive neuronal death, spongiform change, astrocytic [gliosis], and the characteristic clinical syndromes of Prion Disease [3].
PRNP is widely expressed throughout the brain, with highest levels in:
Expression data is available from the Allen Human Brain Atlas.
Mutations in PRNP cause three broad clinical phenotypes of inherited Prion Disease [2][3]:
The most common form of inherited Prion Disease, gCJD typically presents with rapidly progressive dementia, myoclonus, and cerebellar ataxia.
The E200K mutation is the most prevalent cause of gCJD worldwide, with clusters in Libyan Jews, Slovakian populations, and Chilean families [3].
The D178N mutation with valine at codon 129 in cis (D178N-129V) also causes a CJD phenotype [5].
The V210I mutation causes gCJD with low penetrance (approximately 10%) [2][3].
FFI is caused by the D178N mutation when methionine is present at codon 129 in cis (D178N-129M) [5].
This demonstrates a remarkable example of how a single polymorphism can determine entirely different disease phenotypes from the same point mutation.
FFI is characterized by progressive insomnia, dysautonomia, and selective [thalamic] degeneration [3][5].
GSS is primarily associated with the P102L mutation and presents with slowly progressive cerebellar ataxia, followed by dementia.
The A117V mutation causes another variant of GSS [2][3].
GSS is characterized neuropathologically by multicentric amyloid plaques composed of PrP fragments [3].
The methionine/valine polymorphism at codon 129 (M129V) is the most important genetic modifier of Prion Disease susceptibility and phenotype [2][5].
Homozygosity at codon 129 (either M/M or V/V) increases susceptibility to sporadic CJD, and all clinical cases of variant CJD (vCJD) to date have been homozygous for methionine (M/M) at codon 129, except for rare cases
in heterozygous individuals with longer incubation periods [5][6].
In the general European population, approximately 39% are M/M, 51% are M/V, and 10% are V/V [2].
Recent research has expanded the understanding of PRNP beyond classical prion diseases.
PrP^C has been identified as a receptor for [Amyloid-Beta[/proteins/Amyloid-Beta oligomers, suggesting a role in [Alzheimer's disease[/diseases/alzheimers pathogenesis [4].
PrP^C-mediated signaling through [Fyn kinase] may link [amyloid-beta[/entities/amyloid-beta toxicity to tau[/proteins/tau-protein phosphorylation and synaptic dysfunction [4].
Furthermore, somatic PRNP mutations have been identified in the brains of sporadic CJD patients, suggesting that de novo mutations may contribute to apparently sporadic disease [2].
A 2025 review in The Lancet Neurology has comprehensively catalogued genetic causes and modifiers of prion diseases, identifying over 60 pathogenic variants and numerous modifiers beyond codon 129 [3].
The study of Prnp — Prion Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.